Bone and muscle specific circulating microRNAs in postmenopausal women based on osteoporosis and sarcopenia status

Chen, Zhaojing; Bemben, Michael G.

doi:10.1016/j.bone.2018.11.001

Cited by 40 publications

(57 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chen et al also evaluated a panel of eight specific c-miRs in PM LBMD woF patients (n = 46) by a qPCR platform and using a combination of three eRGs to normalize data expression [33]. Although none of the serum levels of these miRs were significantly dysregulated, miR-21-5p and miR-23a-3p showed log 2 FC of >1 (biologically considered up-regulated) and miR-125b-5p of <−1 (biologically considered down-regulated) in LBMD women compared to CTRs.…”

Section: Pm Op/ope Vs Pm Ctrsmentioning

confidence: 99%

Circulating MicroRNAs as Novel Biomarkers for Osteoporosis and Fragility Fracture Risk: Is There a Use in Assessment Risk?

Ciuffi

Donati

Marini

et al. 2020

IJMS

View full text Add to dashboard Cite

Osteoporosis is a multifactorial skeletal disease that is associated with both bone mass decline and microstructure damage. The fragility fractures—especially those affecting the femur—that embody the clinical manifestation of this pathology continue to be a great medical and socioeconomic challenge worldwide. The currently available diagnostic tools, such as dual energy X-ray absorptiometry, Fracture Risk Assessment Tool (FRAX) score, and bone turnover markers, show limited specificity and sensitivity; therefore, the identification of alternative approaches is necessary. As a result of their advantageous features, such as non-invasiveness, biofluid stability, and easy detection, circulating cell-free miRs are promising new potential biomarkers for the diagnosis of osteoporosis and low-traumatic fracture risk assessment. However, due to the absence of both standardized pre-analytical, analytical, and post-analytical protocols for their measurement and universally accepted guidelines for diagnostic use, their clinical utility is limited. The aim of this review was to record all the data currently available in the literature concerning the use of circulating microRNAs as both potential biomarkers for osteoporosis diagnosis and fragility fracture risk evaluation, and group them according to the experimental designs, in order to support a more conscious choice of miRs for future research in this field.

show abstract

Section: Pm Op/ope Vs Pm Ctrsmentioning

confidence: 99%

Circulating MicroRNAs as Novel Biomarkers for Osteoporosis and Fragility Fracture Risk: Is There a Use in Assessment Risk?

Ciuffi

Donati

Marini

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…The aim of a study by Chen et al [ 65 ] was to analyze the serum miRNA profile between patients belonging to four groups, (13 non-OP/nonsarcopenic patients (NN), 46 OP/Osteopenic patients (OO), 15 sarco-osteopenic patients (SOP), and one sarcopenic patient (SP)), by performing qPCR. Eight bone-related miRNAs (miR-1-3p, miR-21-5p, miR-23a-3p, miR-100-5p, miR-125b-5p, miR-133a-3p, and miR-206) were not differentially expressed among the four groups, nor when compared according to the muscle or bone status (51 sarcopenic patients vs. 51 non-SP, and eight OP patients vs. 55 non-OP), even if fold changes of specific miRNAs indicated upregulation or downregulation in OP patients compared to non-OP subjects.…”

Section: Circulating Mirnas As Potential Biomarkers In Bone Fragilmentioning

confidence: 99%

Circulating miRNAs: A New Opportunity in Bone Fragility

et al. 2020

View full text Add to dashboard Cite

Osteoporosis, one of the leading causes of bone fractures, is characterized by low bone mass and structural deterioration of bone tissue, which are associated with a consequent increase in bone fragility and predisposition to fracture. Current screening tools are limited in estimating the proper assessment of fracture risk, highlighting the need to discover novel more suitable biomarkers. Genetic and environmental factors are both implicated in this disease. Increasing evidence suggests that epigenetics and, in particular, miRNAs, may represent a link between these factors and an increase of fracture risk. miRNAs are a class of small noncoding RNAs that negatively regulate gene expression. In the last decade, several miRNAs have been associated with the development of osteoporosis and bone fracture risk, opening up new possibilities in precision medicine. Recently, these molecules have been identified in several biological fluids, and the possible existence of a circulating miRNA (c-miRNA) signature years before the fracture occurrence is suggested. The aim of this review is to provide an overview of the c-miRNAs suggested as promising biomarkers for osteoporosis up until now, which could be helpful for early diagnosis and monitoring of treatment response, as well as fracture risk assessment, in osteoporotic patients.

show abstract

“…Similarly, increased levels of serum miR-483-5p has been found in another study population of OP women vs. non-OP controls [81]. Very recently, an independent study evaluated five bone-specific miRNAs (miR-206, miR-133a-3p, miR-125b-5p, miR-100-5p, and miR-24-3p) in serum samples of postmenopausal OP but results revealed no significant alterations compared to healthy postmenopausal women [82] that, in the case of miR-133a-3p, is in contrast with a previous observation [72]. Circulating miRNAs may be also a potential tool for monitoring the anti-OP therapies effects.…”

Section: Circulating Mirnas In Pre-and Postmenopausal Osteoporosismentioning

confidence: 75%

The Clinical Potential of Circulating miRNAs as Biomarkers: Present and Future Applications for Diagnosis and Prognosis of Age-Associated Bone Diseases

2020

View full text Add to dashboard Cite

Osteoporosis, related fracture/fragility, and osteoarthritis are age-related pathologies that, over recent years, have seen increasing incidence and prevalence due to population ageing. The diagnostic approaches to these pathologies suffer from limited sensitivity and specificity, also in monitoring the disease progression or treatment. For this reason, new biomarkers are desirable for improving the management of osteoporosis and osteoarthritis patients. The non-coding RNAs, called miRNAs, are key post-transcriptional factors in bone homeostasis, and promising circulating biomarkers for pathological conditions in which to perform a biopsy can be problematic. In fact, miRNAs can easily be detected in biological fluids (i.e., blood, serum, plasma) using methods with elevated sensitivity and specificity (RT-qPCR, microarray, and NGS). However, the analytical phases required for miRNAs’ evaluation still present some practical issues that limit their use in clinical practice. This review reveals miRNAs’ potential as circulating biomarkers for evaluating predisposition, diagnosis, and prognosis of osteoporosis (postmenopausal or idiopathic), bone fracture/fragility, and osteoarthritis, with a focus on pre-analytical, analytical, and post-analytical protocols used for their validation and thus on their clinical applicability. These evidences may support the definition of early diagnostic tools based on circulating miRNAs for bone diseases and osteoarthritis as well as for monitoring the effects of specific treatments.

show abstract

Bone and muscle specific circulating microRNAs in postmenopausal women based on osteoporosis and sarcopenia status

Cited by 40 publications

References 38 publications

Circulating MicroRNAs as Novel Biomarkers for Osteoporosis and Fragility Fracture Risk: Is There a Use in Assessment Risk?

Circulating MicroRNAs as Novel Biomarkers for Osteoporosis and Fragility Fracture Risk: Is There a Use in Assessment Risk?

Circulating miRNAs: A New Opportunity in Bone Fragility

The Clinical Potential of Circulating miRNAs as Biomarkers: Present and Future Applications for Diagnosis and Prognosis of Age-Associated Bone Diseases

Contact Info

Product

Resources

About